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ABSTRACT 
Background: Intravenous ketamine has shown rapid antidepressant effects in early trials, 
making it a potentially attractive candidate for depressed patients at imminent risk of suicide. 
The Implicit Association Test (IAT), a performance-based measure of association between two 
concepts, may have utility in suicide assessment. Methods: Twenty-six patients with treatment-
resistant depression were assessed for suicidality 2 hours prior to, and 24 hours following, a 
single subanesthetic dose of intravenous ketamine using the suicidality item of the Montgomery-
Asberg Depression Rating Scale (MADRS-SI). Ten patients also completed IATs assessing 
implicit suicidal associations at comparable time points. In a second study, 9 patients received 
thrice-weekly ketamine infusions over a 12-day period. Results: 24-hours after a single infusion, 
MADRS-SI scores were reduced by an average of 2.08 points on a 0-6 scale (p<.001; d=1.37), 
and 81% of patients received a rating of 0 or 1 post-infusion. Implicit associations between self- 
and escape-related words were also reduced following ketamine (p=.003; d=1.36), with 
reductions correlated across implicit and explicit measures. MADRS-SI reductions were 
sustained for 12 days by repeated-dose ketamine (2.9-point mean reduction; p<.001; d=2.42). 
Conclusions: These preliminary findings support the premise that ketamine has rapid beneficial 
effects on suicidal cognition and warrants further study.  
 
[Registered at ClinicalTrials.gov as trial numbers NCT00419003, “Research Study for Major 
Depressive Disorder: Investigation of Glutamate Medications” and NCT00548964, 
“Continuation Intravenous Ketamine in Major Depressive Disorder”]  
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INTRODUCTION 
Current treatment options for severe mood disorders are limited by the slow time course 
of change in suicidal thoughts. For instance, in major depressive disorder (MDD) patients 
receiving thrice-weekly electroconvulsive therapy, suicidal thoughts persisted in 62% of patients 
after 1 week of treatment and 39% after 2 weeks (1). Conventional antidepressant treatment 
produced slower and less robust response in elderly MDD patients with moderate-to-high suicide 
risk than in non-suicidal patients (2).  
Treatment of acute suicidality is further constrained by inaccuracies in patients’ explicit 
reports of suicidal thoughts (3, 4). The Implicit Association Test (IAT)(5) may be useful as a 
behavioral measure of suicidal cognition, as the task is reliable (6) and resistant to attempts to 
intentionally control its outcome (7). Furthermore, when socially “taboo" cognitions are assessed 
(e.g., prejudicial attitudes), the IAT is a superior predictor of future behavior relative to explicit 
measures (8). IAT variants assessing suicide- and self-injury-related cognition have shown 
promise in discriminating between self-injurious and non-injurious adolescents (9), suicidal and 
non-suicidal adolescents (3), and adult suicide attempters and non-attempters presenting to a 
psychiatric emergency department (10).  
Early evidence suggests that a single subanesthetic dose of intravenous (IV) ketamine, a 
glutamate-modulating agent, acutely reduces depressive symptoms in approximately 70% of 
MDD patients 24 hours after infusion (11-13). We tested ketamine’s impact on suicidal cognition 
in a sample of adults with treatment-resistant depression (TRD). We hypothesized that ketamine 
would yield rapid, correlated reductions in explicit and implicit suicidal indices. Furthermore, we 
expected that rapid initial reductions in explicit suicidality would be sustained through repeated 
ketamine infusions. Price et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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MATERIALS AND METHODS 
Twenty-six TRD patients were recruited via media advertisement or clinician referral. 
Treatment-resistance was defined as two or more failed, adequate antidepressant trials in the 
current episode, as determined by the Antidepressant Treatment History Form (14). DSM-IV-TR 
diagnoses of MDD were established by SCID-I/P
 interview. Eligible participants had moderate-
to-severe depression (Inventory of Depressive Symptomatology score ≥32)(15); were 
psychotropic medication-free for ≥2 weeks prior to infusion (4 weeks for fluoxetine); free of 
substance abuse/dependence for ≥6 months; denied lifetime use of ketamine and PCP; had no 
lifetime history of psychotic disorder, mania or hypomania; and had no clinically unstable 
medical or neurological conditions. Patients whom research team psychiatrists deemed unsafe for 
study participation due to highly active suicidality were excluded.  
Patients were admitted to a private hospital room for a 28-hour period for racemic 
ketamine hydrochloride infusion (0.5 mg/kg diluted in saline, administered over 40 minutes by 
IV pump(12)) and cardiorespiratory monitoring. Patients were assessed for depressive symptoms 
150 minutes prior to, and 24-hours following, infusion using the Montgomery-Asberg 
Depression Rating Scale (MADRS), a 10-item clinician-administered measure that includes a 
single suicidality item (Table 1)(16). MADRS raters held graduate degrees and achieved high 
inter-rater reliability both during training and when co-rating a random sample of videotaped 
study interviews (ICC’s≥0.96). The timeframe for post-infusion MADRS was modified to reflect 
the period since last assessment. Ketamine’s antidepressant effects in this sample (not including 
suicidality analysis) have been reported previously (13).  Price et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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A subset of patients (n=12)
1 completed the IAT and the 21-item self-report Beck Scale 
for Suicidal Ideation (BSI)(17) at baseline. Ten patients repeated these measures 24-hours post-
infusion
2 (Supplement A).  
A distinct subset of single-dose ketamine responders (n=10)
3 enrolled in a subsequent 
study of repeated-dose IV ketamine. Detailed methods, tolerability, and antidepressant effects 
will be reported separately (18). Following a Day 1 infusion identical to that described above, 
patients were assessed for 24-hour antidepressant response (MADRS≤50% of baseline score). 
Responders (9/10 participants) then received up to 5 additional infusions (Days 3,5,8,10,12) 
identical to the first, except that patients were assessed and discharged 4-hours post-infusion.  
Table 2 presents clinical and demographic characteristics of the three samples. All 
participants signed informed consent. The Mount Sinai School of Medicine Institutional Review 
Board approved procedures.  
Implicit Association Test (IAT) 
Two  recently  developed  variants  of  the  IAT  (IAT-Death,  assessing  the  strength  of 
association between words related to “Death” and “Me”; IAT-Escape, assessing associations 
between  “Escape”  and  “Me”)  were  selected  based  on  the  hypothesis  that  individuals 
contemplating suicide would be characterized by greater self-identification with death (relative 
to  life)  and  escape  (relative  to  stay).  Preliminary  evidence  suggests  these  associations  are 
stronger in suicide attempters than non-attempters (10). IATs were administered and scored in 
accordance  with  recommended  procedures  (19)  and  followed  a  design  described  previously 
(9)(Supplement  B).  “Escape=Me”  and  “Death=Me”  D-scores  were  calculated  for  each 
                                                 
1 IAT and BSI data were collected from patients enrolled during the latter half of the enrollment 
period only 
2 Time constraints prevented post-infusion data collection in 2 patients 
3 3 participants in the repeated-dose study were also participants in the IAT subsample Price et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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participant, where D=[(mean RT during Escape=Me [or Death=Me] block) – (mean RT during 
Stay=Me [or Life=Me] block) ÷ (SD of RT across all trials)].  
Statistical Analysis 
A composite suicidality index (SIcomposite) was calculated by summing z-scores on the BSI 
and MADRS suicidality item (MADRS-SI). Change scores for all measures were calculated as 
24-hour value – baseline value. Baseline and post-ketamine scores were compared by paired t-
tests, with effect sizes calculated as Cohen’s d (20), and by repeated-measures analysis of 
covariance (ANCOVA). Due to violation of Small’s test for multivariate normality in several 
baseline measures, baseline correlations were calculated nonparametrically with Spearman’s rho. 
Correlations for change scores were calculated using Pearson’s r. Two-tailed alpha level was set 
at .05, unadjusted.  
RESULTS 
A single infusion of ketamine reduced scores on the MADRS-SI by an average of 2.08 
points on a 0-6 scale (t25=6.42, p<.001; d=1.37), with 81% of patients achieving a rating of 0 or 1 
24-hours post-infusion (Table 3; Figure 1). Of the 13 patients with clinically significant suicidal 
ideation at baseline (MADRS-SI scores ≥4), 8 (62%) received a rating of 0 or 1 24-hours post-
infusion, 3 (23%) endorsed fleeting suicidal thoughts (ratings of 2 or 3), while 2 (15%) remained 
at or above a rating of 4. With change scores in non-suicide-related MADRS items (MADRS-
totalnonSI) entered as a covariate, repeated-measures ANCOVA of baseline and 24-hour MADRS-
SI scores was not significant (F1,24=.38, p=.54), suggesting ketamine’s anti-suicidal effects are 
mediated by depression reduction.   
In the TRD subsample completing baseline IATs (n=12), stronger “Escape=Me” implicit 
associations were associated with greater MADRS-SI scores (rho=.60; p=.04), and marginally Price et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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with SIcomposite scores (rho=.57; p=.052), but not with non-suicide-related depression severity 
(MADRS-totalnonSI: rho=.24; p=.46). Baseline “Death=Me” associations were unrelated to other 
measures (ps >.34).  In patients who repeated the measures 24-hours post-infusion (n=10), there 
was a reduction in “Escape=Me” associations (t9=3.76; p=.006; d=1.37)(Figure 2) and in BSI 
(t9=3.15; p=.012) and MADRS-SI (t9=5.24; p<.001). “Death=Me” associations were not 
significantly changed (t9=.658; p=.52). “Escape=Me” reductions were correlated with reductions 
in BSI (r=.65; p=.042), SIcomposite (r=.64; p=.048), and MADRS-SI at the trend level (r=.57; 
p=.09), but not with MADRS-totalnonSI changes (r=-.03; p=.94). “Death=Me” changes showed a 
trend-level association with BSI changes only (r=.60; p=.06). Most zero-order correlations were 
maintained or increased after controlling for change in MADRS-totalnonSI and baseline SIcomposite 
(Table 4).  
In patients who subsequently enrolled in the repeated-dose ketamine study (n=10), the 
first infusion again significantly reduced MADRS-SI scores (2.8-point mean decrease; t9=5.47, 
p<.001; d=2.17), with 90% of patients receiving a 24-hour rating of 0 (Table 3; Figure 1). Acute 
reductions were maintained throughout the 12-day treatment period by the 9 patients receiving 
repeated infusions (baseline-to-day-12 mean decrease=2.89; t8=5.12, p=.001; d=2.42), with no 
patient scoring >2 at any post-baseline assessment (before and after each infusion).  
DISCUSSION 
  These preliminary findings support the premise that a single subanesthestic dose of IV 
ketamine has rapid effects on suicidal cognition in TRD, and that acute improvements in 
suicidality can be sustained through repeated ketamine infusions. Confidence intervals for 
MADRS-SI suggested moderate to very large effects, despite small sample sizes.  Price et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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  An IAT assessing the association between ‘Me’ and ‘Escape’ was related to explicit 
suicidal ideation at baseline and showed sensitivity to therapeutic change, an important criterion 
if the IAT is to have utility as a clinical assessment tool. Associations between ‘Me’ and ‘Death’ 
did not change as predicted, suggesting that the implicit representation of suicide in TRD might 
more closely relate to the concept of escape than to death itself. “Death=Me” associations were 
low at baseline, possibly limiting room for improvement. Prospective studies in high-risk 
samples should test whether the IAT can improve prediction of suicide risk in clinical settings, 
where motivation to conceal suicidal thoughts may exist (4). The IAT might also be useful in 
revealing psychological mechanisms of change. For instance, mediational analysis in larger 
samples could test the hypothesis that ketamine reduces depressed mood in suicidal patients, 
thereby decreasing implicit desire to escape from an unbearable emotional state, leading to 
downstream reductions in explicit suicidal thoughts.  
  The rapid onset and maintenance of improvement we observed suggests that IV 
ketamine, administered in the hospital setting with appropriate safety monitoring, may offer an 
attractive therapy for acutely suicidal depressed patients. Whether high-risk patients with 
markedly active suicidality will respond similarly remains an open question. Controlled studies 
are needed to establish whether ketamine is efficacious in such samples and whether decreased 
suicidality, once achieved, can be maintained through alternative pharmacological or 
psychosocial interventions. Given that all three datasets analyzed here were obtained from a 
single group of patients, these findings require independent replication. 
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Table 1. Montgomery-Asberg Depression Rating Scale scoring guidelines for item 10: “Suicidal Thoughts” 
Score	 ﾠ Description	 ﾠ
0	 ﾠ “Enjoys life or takes it as it comes.”	 ﾠ
1	 ﾠ        [none provided]	 ﾠ
2	 ﾠ “Weary of life. Only fleeting suicidal thoughts.”	 ﾠ
3	 ﾠ        [none provided]	 ﾠ
4	 ﾠ “Probably better off dead.  Suicidal thoughts are common, and suicide is considered as a 
possible solution, but without specific plans or intention.”	 ﾠ
5	 ﾠ        [none provided]	 ﾠ
6	 ﾠ “Explicit plans for suicide when there is an opportunity. Active preparation for suicide.”	 ﾠPrice et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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Table 2. Baseline descriptive and clinical characteristics of full sample treated with single infusion intravenous ketamine; subsample 
who subsequently completed the repeated infusions study; and IAT subsample who completed additional implicit and explicit 
measures of suicidality at baseline  
	 ﾠ
Single Infusion 
Sample  
(n=26)
†	 ﾠ
IAT Subsample 
(n=12)	 ﾠ
Repeated 
Infusions 
Subsample 
(n=10)	 ﾠ
Age, mean (SD), y	 ﾠ 48.2 (11.8)  
  	 ﾠ
50.1 (10.3) 
  	 ﾠ
51.4 (14.6)	 ﾠ
Female, No. (%)	 ﾠ 10 (39%)	 ﾠ 5 (42%)	 ﾠ 5 (50%)	 ﾠ
Non-Hispanic Caucasian, No. (%)	 ﾠ 18 (69%)	 ﾠ 8 (67%)	 ﾠ 7 (70%)	 ﾠ
IQ, mean (SD)	 ﾠ 115.0 (10.3)	 ﾠ 118.7 (10.2)	 ﾠ 115.7 (11.8)	 ﾠ
Median household annual income 	 ﾠ $15,000-24,999	 ﾠ $10,000-14,999	 ﾠ $15,000-24,999	 ﾠ
Time Since Illness Onset, mean (SD), y	 ﾠ 29.3 (13.3)	 ﾠ 29.7 (10.5)	 ﾠ 29.6 (13.0)	 ﾠ
Age-of-Onset, mean (SD), y	 ﾠ 18.5 (12.2)	 ﾠ 20.4 (11.2)	 ﾠ 20.9 (15.4)	 ﾠ
Number of Episodes, mean (SD)	 ﾠ 1.9 (1.7)	 ﾠ 2.3 (2.1)	 ﾠ 2.1 (1.7)	 ﾠ
Duration of Current Episode >= 2y, No. (%)	 ﾠ 26 (100%)	 ﾠ 12 (100%)	 ﾠ 10 (100%)	 ﾠ
Number of Failed Antidepressant Trials in Current 
Episode, mean (SD) 	 ﾠ
6.0 (4.1)	 ﾠ 6.8 (3.9)	 ﾠ 7.1 (4.2)	 ﾠ
History of Suicide Attempts, No. (%)	 ﾠ 5 (19%)	 ﾠ 3 (25%)	 ﾠ 1 (10%)	 ﾠPrice et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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Clinically Significant Suicidal Ideation (MADRS-SI  
score >=4), No. (%) 
       MADRS-SI=4 
       MADRS-SI=5 
       MADRS-SI=6	 ﾠ
13 (50%) 
 
10 (38.5%) 
3 (11.5%) 
0 	 ﾠ
6 (50%) 
 
5 (41.7%) 
1 (8.3%) 
0	 ﾠ
6 (60%) 
 
5 (50%) 
1 (10%) 
0	 ﾠ
Note: MADRS-SI = Montgomery-Asberg Depression Rating Scale (16) suicidality item; IAT = Implicit Association Test (5)
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Table 3. Ketamine effects on explicit and implicit suicidality 
 
	 ﾠ Single Infusion Study (n=26)	 ﾠ IAT Subsample (n=10)	 ﾠ Repeated Infusions Study (n=10)	 ﾠ
 
Measure	 ﾠ
 
Mean (SD)	 ﾠ
Effect Size:  
Cohen’s d [95% CI]	 ﾠ
 
Mean (SD)	 ﾠ
Effect Size:  
Cohen’s d [95% CI]	 ﾠ
 
Mean (SD)	 ﾠ
Effect Size:  
Cohen’s d [95% CI]	 ﾠ
MADRS total 
    Baseline 
    Day 2: 24-hours after infusion 1 
    Day 12: 4-hours after infusion 6  	 ﾠ
 
36.92 (5.41) 
14.85 (13.14)*** 
--	 ﾠ
 
 
d=2.11 [1.25-2.97] 
--	 ﾠ
 
37.80 (5.8) 
9.40 (8.9)*** 
--	 ﾠ
 
 
d=3.79 [1.21-6.37] 
--	 ﾠ
 
32.70 (6.43) 
8.10 (4.63)*** 
5.11 (3.66)***
 †	 ﾠ
 
 
d=4.43 [0.89-7.97] 
d=5.98 [1.52-10.44]	 ﾠ
MADRS-SI 
    Baseline 
    Day 2: 24-hours after infusion 1 
    Day 12: 4-hours after infusion 6	 ﾠ
 
2.85 (1.6) 
0.77 (1.4)*** 
--	 ﾠ
 
 
d=1.37 [0.79-1.95] 
--	 ﾠ
 
2.90 (1.7) 
0.40 (.97)*** 
--	 ﾠ
 
 
d=1.67 [0.70-2.64] 
--	 ﾠ
 
3.00 (1.63) 
0.20 (0.63)*** 
0.00 (0.00)***
 †	 ﾠ
 
 
d=2.17 [0.75-3.59] 
d=2.42 [1.20-3.63]	 ﾠ
BSI 
    Baseline 
    Day 2: 24-hours after infusion 1	 ﾠ
 
-- 
--	 ﾠ
 
-- 
--	 ﾠ
 
8.00 (9.3) 
3.3 (7.8)*	 ﾠ
 
 
d=0.53 [0.18-0.87]	 ﾠ
 
-- 
--	 ﾠ
 
-- 
--	 ﾠ
IAT: Escape=Me 
    Baseline 
    Day 2: 24-hours after infusion 1	 ﾠ
 
-- 
--	 ﾠ
 
-- 
--	 ﾠ
 
-.04 (.31) 
-.53 (.40)**	 ﾠ
 
 
d=1.36 [0.38-2.34]	 ﾠ
 
-- 
--	 ﾠ
 
-- 
--	 ﾠ
IAT: Death=Me 
    Baseline 
    Day 2: 24-hours after infusion 1	 ﾠ
 
-- 
--	 ﾠ
 
-- 
--	 ﾠ
 
-.48 (.63) 
-.28 (.43) (ns)	 ﾠ
 
 
d=-0.38 [-1.56-0.79]	 ﾠ
 
-- 
--	 ﾠ
 
-- 
--	 ﾠ
Note: TRD = treatment-resistant depression; MADRS = Montgomery-Asberg Depression Rating Scale (16); MADRS-SI = MADRS 
Suicidality Item; BSI = Beck Scale for Suicidal Ideation (17); IAT = Implicit Association Test (5) 
*** p<.001; ** p < .01; * p < .05; ns = not significant; baseline and post-infusion scores compared by paired t-tests; baseline-to-post 
infusion effect size (d) calculated from means, SDs, and pre-post correlation coefficients (20)
 
†n=9 for Day 12 assessments 
 Price et al.                                                 Effects of Ketamine on Explicit and Implicit Suicidality 
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Table 4. Partial correlations between change scores (24-hours – baseline) in implicit and explicit suicidality measures, controlling for 
change in other depressive symptoms (MADRS, excluding suicidality item) 
	 ﾠ MADRS-SI	 ﾠ BSI	 ﾠ SIcomposite	 ﾠ
IAT: Escape=Me	 ﾠ .74 (p=.022)	 ﾠ .72 (p=.028)	 ﾠ .78 (p=.014)	 ﾠ
IAT: Escape=Me, adding baseline SIcomposite 
as an additional covariate 
	 ﾠ
.64 (p=.086)	 ﾠ .60 (p=.118)	 ﾠ .71 (p=.048)	 ﾠ
IAT: Death=Me	 ﾠ .34 (p=.366)	 ﾠ .69 (p=.038)	 ﾠ .55 (p=.122)	 ﾠ
IAT: Death=Me, adding baseline SIcomposite as 
an additional covariate	 ﾠ
.31 (p=.460)	 ﾠ .80 (p=.016)	 ﾠ .65 (.078)	 ﾠ
Note: MADRS = Montgomery-Asberg Depression Rating Scale (16); MADRS-SI = MADRS Suicidality Item; BSI = Beck Scale for 
Suicidal Ideation (17); SIcomposite = composite suicidality index: sum of z-scores on BSI and MADRS-SI; IAT = Implicit Association 
Test (5) 
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FIGURE LEGENDS 
FIGURE 1. Individual patient scores on the Montgomery-Asberg Rating Scale—Suicide item at 
baseline (Day 1; 150 minutes prior to infusion), 24-hours following a single subanesthetic 
infusion of ketamine (Day 2), and 4-hours following the final repeated infusion (Day 12 of study; 
Panel 2 only). 
FIGURE 2. Mean IAT-Escape D-scores (± SEM) representing the strength of association 
between words related to “Me” and words related to “Escape” at baseline and 24-hours following 
a single subanesthetic infusion of ketamine. D-scores calculated as D = [(mean response latency 
during Escape/Me block – mean response latency during Escape/Not Me block) ÷ SD of 
response latency across all trials]. More positive D-score indicates stronger implicit self-
identification with words related to “Escape,” in comparison to words related to “Stay.” 
 Price et al.                                                                                                    
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Figure 1. 
 
 
         
 
   
Single-infusion study 
n=3  
n=10 
n=3 
n=4  
n=3 
n=3  
 
                = group mean  n=1  
n=1 
n=1 
n=4  
n=2 
n=17  
Baseline        24-hours post 
(n=26)                single infusion (n=26) Price et al.                                                                                                    
  19 
 
              
 
 
 
Repeated-infusions study 
n=1; patient exited protocol due to 
inadequate antidepressant response to 
infusion 1 
 
n=9 
n=1 
n=5 
n=1 
n=2 
n=1 
n=9 
Baseline        24-hours post          4-hours post 
(n=10)                   infusion 1 (n=10)                 infusion 6 (n=9) 
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Figure 2. 
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(N=14)  
* IAT and BSI were added as baseline and outcome measures 
during latter half of study enrollment period.  
*  
‡ Time constraints prevented post-infusion IAT 
and BSI data collection in 2 of the 12 patients who 
completed all measures at baseline. 
‡ 
(N=16)  
Supplement 1 
 
Supplemental Figure 1. Flow chart of events in single-dose and repeated-dose studies 
Baseline 
MADRS 
(N=26) 
Baseline 
IAT, BSI 
(N=12) 
Single-
Dose 
Infusion 
(N=26) 
24-hour 
IAT, BSI 
(N=10) 
24-hour 
MADRS 
(N=26) 
Non-
responders 
(N=8) 
Responders, 
no adverse 
events (N=18) 
Relapsed, 
potentially 
eligible for 
Repeated-
Dose Study 
(N=16) 
Participated 
in 
Repeated-
Dose Study 
(N=10) 
Did not enroll 
prior to 
completion of 
study (N=6) 
3 IAT subsample participants were also eventual participants in the repeated-dose study  Price et al.                                                                                                    
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Supplement 2 
The Implicit Association Test (IAT) rests on the assumption that it is easier to map two concepts onto a single behavioral response (e.g., left 
key press) when they are closely associated than when they are loosely associated. The two IATs (IAT-Death; IAT-Escape) were completed in 
counterbalanced order on a Dell laptop computer running Inquisit (Millisecond Software, Seattle, WA). Participants were instructed to classify 
stimuli appearing at the center of the screen by pressing the “e” key for words belonging to categories on the left of the screen and the “i” key for 
words belonging to categories on the right. In the IAT-Death, a series of words related to death (suicide, die, dead, deceased, lifeless) or life (alive, 
live, survive, thrive, breathing) were presented in random order, intermixed with a series of self-relevant (I, Myself, My, Mine, Self) or other-relevant 
(They, Them, Their, Other, Theirs) words. Category labels (“Death,” “Life,” “Me,” “Not Me”) remained in the upper left and right corners of the 
screen throughout the task (Supplemental Figure 2).  
 
Supplemental Figure 2. Schematic of Implicit Association Test 
left 
key 
right 
key 
Concept (Death and Life) 
and attribute (Me and Not 
Me) labels appear in top 
corners of the screen 
Stimuli to be categorized 
appear in center of the 
screen 
Correct behavioral 
response  
Death                 Life 
Me               Not Me 
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Stimuli remained onscreen until the correct response was made. Incorrect classifications resulted in the presentation of a red 
“X” below the stimulus. In the first critical block (presented in randomized order) the category labels “Death” and “Me” appeared on 
the same side of the screen and thus required the same key response, while “Life” and “Not Me” appeared on the opposite side. In the 
second critical block, the category pairings were reversed—“Death” and “Not Me” required the same key press, as did “Life” and 
“Me.” The relative strength of association between self and death was inferred from the speed of responses during these two blocks. A 
D score was calculated for each participant, where D=[(mean response latency during Death/Me block – mean response latency during 
Death/Not Me block) ÷ SD of response latency across all trials]. The IAT-Escape followed an identical design with words related to 
escape (exit, quit, end, leave, depart) and stay (continue, remain, hold on, persist, endure), as well as self-referential and other-
referential words (as before), classified under the headings “Escape,” “Stay,” “Me,” and “Not Me.” 
   
 